Vebreltinib for Advanced or Metastatic CCS

"Vebreltinib： Oral capsule formulation, specification: 100 mg/capsule. Subjects will start medication after enrollment, 200 mg bid po, until disease progression, intolerable toxicity, or death.~If disease progression is observed in the first evaluation (2 months after the first administration), if the investigator deems it possible to continue benefiting from targeted therapy, targeted therapy combined with best supportive care can be continued until the second evaluation (4 months)."

standard treatment like chemotherapy, PD1, Anlotinib……